Moderna (MRNA) Preferred Stock Liabilities (2016 - 2017)
Moderna (MRNA) reported Preferred Stock Liabilities of $1.2 billion for Q4 2017, little changed year-over-year from $1.2 billion in Q4 2016, and little changed quarter-over-quarter from $1.2 billion in Q4 2016.
Moderna (MRNA) Preferred Stock Liabilities (2016 - 2017) Analysis & Trends
Moderna (MRNA) has 2 years of Preferred Stock Liabilities data on file, last reported at $1.2 billion in Q4 2017.
- Preferred Stock Liabilities for Q4 2017 came in at $1.2 billion, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2017 was $1.2 billion (changed 0.0% YoY), and the FY2017 annual result was $1.2 billion, changed 0.0% from the prior year.
- Preferred Stock Liabilities held at $1.2 billion in Q4 2017 per MRNA's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $1.2 billion in Q4 2016 and troughed at $1.2 billion in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Moderna | 25.27 Bn | 20.06 Bn | -566.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1.18 Bn |
| Dec 31, 2016 | 1.18 Bn |